MedTrace Logo

Safety and Efficacy Study of NV-101 in Dental Patients

NCT00154167 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2005-09-14

No results posted yet for this study

Summary

The purpose of this study was:

* to determine if NV-101 accelerates recovery from numbness compared to placebo
* to evaluate safety of NV-101

Conditions

  • Soft Tissue Anesthesia (Numbness)

Interventions

DRUG

NV-101 (phentolamine mesylate solution)

Sponsors & Collaborators

  • Novalar Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Royce Morrison, MD · Northwest Kinetics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-02-28
Completion
2003-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00154167 on ClinicalTrials.gov